131I-MIBG Therapy for Neuroblastoma
Author Information
Author(s): Garaventa A, Bellagamba O, Piccolo M S Lo, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia G P, Cabria M, Scopinaro G, Claudiani F, Bernardi B De
Primary Institution: Department of Haematology–Oncology, Giannina Gaslini Children’s Hospital, Genova-16147, Italy
Hypothesis
Incorporating 131I-metaiodobenzylguanidine (131I-MIBG) in treatment regimens may improve tumor response in children with advanced neuroblastoma.
Conclusion
131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy.
Supporting Evidence
- The study included 43 neuroblastoma patients who had not achieved complete response from first-line therapy.
- The most common acute side-effect was thrombocytopenia.
- Complete response was documented in one stage 4 patient.
- Partial response was observed in 12 patients.
- Twenty-four patients are alive at a median of 59 months from diagnosis.
Takeaway
Doctors used a special treatment called 131I-MIBG to help kids with a type of cancer called neuroblastoma, and it seemed to help some of them get better.
Methodology
The study involved 43 neuroblastoma patients who received varying doses of 131I-MIBG after not achieving complete response from first-line therapy.
Limitations
Logistic problems hamper prospective and coordinated studies, and long-term toxicity can be severe.
Participant Demographics
Patients were older than 1 year at diagnosis, with 13 in stage 3 and 30 in stage 4.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website